Sanofi — Director's Dealing 2020

Jul 24, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Inozyme Pharma, Inc. (INZY)
CIK: 0001693011
Period of Report: 2020-07-23

Reporting Person: Sanofi (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Convertible Preferred Stock (par value, $0.0001)	$		Common Stock (438875)		Indirect

Footnotes

F1: Sanofi is the beneficial owner of 3,279,720 Shares of Series A Convertible Preferred Stock of the Issuer through its wholly owned subsidiary Aventis Inc.

F2: The Series A Convertible Preferred Stock is convertible on a 7.473-for-one basis into the number of shares of Common Stock of the Issuer as shown in Column 3 at any time at the holder's election, and automatically upon the closing of the initial public offering of the Issuer without payment or further consideration.